皇家华人

header-logo
GettyImages-609179959-hero
headshot

Deepak Kilari, MD

Associate Professor

view physician profile

Locations

  • Froedtert Hospital
  • Cancer Center - Froedtert Hospital

Specialties

  • Hematology
  • Medical Oncology

Languages

  • English, Telugu, Hindi

New & Established Patients Call

Education

  • MD - Doctor of Medicine

Biography

Deepak Kilari, MD, is an assistant professor in the division of hematology and oncology at the 皇家华人. Dr. Kilari moved back to the United States after finishing medical school at Andhra Medical College, India, to finish his internal medicine training at New York Methodist Hospital. In the course of his residency, he developed an interest in Oncology during his rotations at the Memorial Sloan Kettering Cancer Center, New York. Subsequently, he completed a fellowship in hematology and oncology at the University of Rochester, where he also served as a chief fellow. He received the American Society of Clinical Oncology (ASCO) Foundation Merit award in 2013. Dr. Kilari practices at Froedtert & the 皇家华人 Clinical Cancer Center and Moorland Reserve Clinic where he specializes in the management of patients with Genitourinary malignancies.

Research Interests

Dr. Kilari's clinical research interests focus on the development of better treatment options for patients with genitourinary malignancies. Dr. Kilari is Board Certified in Medical Oncology and Hematology.

Publications

  • (Li Q, Huang CC, Huang S, Tian Y, Huang J, Bitaraf A, Dong X, Nevalanen MT, Patel M, Wong J, Zhang J, Manley BJ, Park JY, Kohli M, Gore EM, Kilari D, Wang L.) medRxiv. 2024 Oct 17 PMID: 37904926 PMCID: PMC10615016 10/31/2023

  • (Graff JN, Hoimes CJ, Gerritsen WR, Vaishampayan UN, Elliott T, Hwang C, Ten Tije AJ, Omlin A, McDermott RS, Fradet Y, Tagawa ST, Kilari D, Ferrario C, Uemura H, Jones RJ, Fukasawa S, Peer A, Niu C, Poehlein CH, Qiu P, Suttner L, de Wit R, Schloss C, de Bono JS, Antonarakis ES.) Prostate Cancer Prostatic Dis. 2024 Aug 12 PMID: 39134652 SCOPUS ID: 2-s2.0-85201272323 08/13/2024

  • (Graham LS, Henderson NC, Kellezi O, Hwang C, Barata PC, Bilen MA, Kilari D, Pierro M, Thapa B, Tripathi A, Mo G, Labriola M, Park JJ, Rothstein S, Garje R, Koshkin VS, Patel VG, Dorff T, Armstrong AJ, McKay RR, Alva A, Schweizer MT.) JCO Precis Oncol. 2024 Aug;8:e2400014 PMID: 39178368 PMCID: PMC11346579 SCOPUS ID: 2-s2.0-85202867052 08/23/2024

  • (Broderick A, Pan E, Li J, Chu A, Hwang C, Barata PC, Cackowski FC, Labriola M, Ghose A, Bilen MA, Kilari D, Thapa B, Piero M, Graham L, Tripathi A, Garje R, Koshkin VS, Hernandez E, Dorff TB, Schweizer MT, Alva AS, McKay RR, Armstrong AJ.) Prostate Cancer Prostatic Dis. 2024 Jul 17 PMID: 39019980 07/18/2024

  • (Park JJ, Chu A, Li J, Ali A, McKay RR, Hwang C, Labriola MK, Jang A, Kilari D, Mo G, Ravindranathan D, Graham LS, Sokolova A, Tripathi A, Pilling A, Jindal T, Ravindra A, Cackowski FC, Sweeney PL, Thapa B, Amery TS, Heath EI, Garje R, Zakharia Y, Koshkin VS, Bilen MA, Schweizer MT, Barata PC, Dorff TB, Cieslik M, Alva AS, Armstrong AJ.) JCO Precis Oncol. 2024 Apr;8:e2300567 PMID: 38579192 PMCID: PMC11018169 SCOPUS ID: 2-s2.0-85198519208 04/05/2024

  • (Aggarwal R, Heller G, Hillman DW, Xiao H, Picus J, Taplin ME, Dorff T, Appleman L, Weckstein D, Patnaik A, Bryce A, Shevrin D, Mohler J, Anderson D, Rao A, Tagawa S, Tan A, Halabi S, Dooley K, O'Brien P, Chen R, Ryan CJ, Eggener SE, Morris MJ, EORTC-55994 Study Group.) J Clin Oncol. 2024 Apr 01;42(10):1114-1123 PMID: 38261983 PMCID: PMC11637124 SCOPUS ID: 2-s2.0-85186714362 01/23/2024

  • (Zengin ZB, Henderson NC, Park JJ, Ali A, Nguyen C, Hwang C, Barata PC, Bilen MA, Graham L, Mo G, Kilari D, Tripathi A, Labriola M, Rothstein S, Garje R, Koshkin VS, Patel VG, Schweizer MT, Armstrong AJ, McKay RR, Alva A, Dorff T.) Prostate Cancer Prostatic Dis. 2024 Feb 22 PMID: 38383885 02/22/2024

  • (Obasi J, Sharma K, De Sarkar N, Antonarakis ES, Kilari D.) Clinical Genitourinary Cancer. December 2024;22(6) SCOPUS ID: 2-s2.0-85203009546 12/01/2024

  • (Thapa B, De Sarkar N, Giri S, Sharma K, Kim M, Kilari D.) Cancer Manag Res. 2024;16:1267-1283 PMID: 39308935 PMCID: PMC11416116 SCOPUS ID: 2-s2.0-85204934732 09/23/2024

  • (Davis NB, Kilari D, Kessler ER, Smelser WW.) Frontiers in Oncology. 2024;14 SCOPUS ID: 2-s2.0-85206092308 01/01/2024

  • (Hwang C, Henderson NC, Chu SC, Holland B, Cackowski FC, Pilling A, Jang A, Rothstein S, Labriola M, Park JJ, Ghose A, Bilen MA, Mustafa S, Kilari D, Pierro MJ, Thapa B, Tripathi A, Garje R, Ravindra A, Koshkin VS, Hernandez E, Schweizer MT, Armstrong AJ, McKay RR, Dorff TB, Alva AS, Barata PC.) JAMA Netw Open. 2023 Sep 05;6(9):e2334208 PMID: 37721753 PMCID: PMC10507489 SCOPUS ID: 2-s2.0-85171513698 09/18/2023

  • (Thapa B, Nelson A, Kilari D.) Integrating Multidisciplinary Treatment for Advanced Renal Cell Carcinoma. 1 November 2023:309-342 SCOPUS ID: 2-s2.0-85198394501 11/01/2023

Publications of from the

© 2024 皇家华人.  All rights reserved.  | Terms and Privacy 

Non-Discrimination Statement
The 皇家华人 (MCW) is committed to fostering a diverse community of outstanding faculty, staff, and students, as well as ensuring equal educational opportunity, employment, and access to services, programs, and activities, without regard to an individual's race, color, national origin, religion, age, disability, sex, gender identity/expression, sexual orientation, marital status, pregnancy, predisposing genetic characteristic, or military status. Employees, students, applicants or other members of the MCW community (including but not limited to vendors, visitors, and guests) may not be subjected to harassment that is prohibited by law or treated adversely or retaliated against based upon a protected characteristic. MCW’s policy as well as federal and state laws and regulations prohibit unlawful discrimination and harassment.